[en] Fifty patients affected by sickle cell anaemia underwent transplantation of HLA-identical haematopoietic stem cells (bone marrow, 48; cord blood, 2). Two groups of patients were considered for transplantation. Group 1 included 36 permanent residents of a European country who, retrospectively, met the inclusion criteria accepted at a consensus conference held in Seattle in 1990, wherein children were selected because they already had evidence of a morbid course. Group 2 included 14 patients who were transplanted earlier, had not received more than three blood transfusions and were transplanted because they had decided to return to their country of origin. Kaplan-Meier estimates of overall survival, event-free survival and disease-free survival at 11 years of the whole grafted population are 93, 82 and 85%, respectively. In group 1, overall survival, EFS and DFS were 88, 76 and 80% and in group 2, 100, 93 and 93%, respectively. Clinical manifestations of the disease, as well as disease associated haemolytic anaemia, disappeared in all successfully treated patients. Recovery of spleen function was present in seven out of 10 evaluated patients. Adverse events (death, absence of engraftment, mixed chimerism and relapse) occurred more frequently in group 1 than in group 2 (25% vs 7%, P< 0.001). Acute graft-versus-host disease (GVHD) was present in 20 patients (grade I or II, 19; grade III, 1), chronic GVHD in 10 (limited, 7; extensive, 3). One patient developed an acute myeloid leukaemia. Gonadal dysfunction was present in all patients (six boys and eight girls) transplanted close to or after puberty, although transient in one adolescent girl.
Disciplines :
Hematology
Author, co-author :
Vermylen, C.
Cornu, G.
Ferster, Aline
Brichard, B.
Ninane, J.
Ferrant, A.
Zenebergh, A.
Maes, P.
Dhooge, C.
Benoit, Y.
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Platt OS, Brambilla DJ, Rosse WF et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. New Engl J Med 1994; 330: 1639-1644.
Charache S, Terrin ML, Moore RD et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New Engl J Med 1995; 332: 1317-1322.
Ferster A, Vermylen C, Cornu G et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 1996; 88: 1960-1964.
Johnson FL, Look AT, Gockerman J et al. Bone marrow transplantation in a patient with sickle cell anemia. New Engl J Med 1984; 311: 780-783.
Vermylen C, Fernandez Robles E, Ninane J, Cornu G. Bone marrow transplantation in five children with sickle cell anaemia. Lancet 1988; 1: 1427-1428.
Vermylen C, Cornu G. Bone marrow transplantation for sickle cell anemia. Curr Opin Hematol 1996; 3: 163-166.
Walters MC, Patience M, Leisenring W et al. Bone marrow transplantation for sickle cell disease. New Engl J Med 1996; 335: 369-376.
Storb R, Weiden PL, Sullivan KM et al. Second marrow trans- m plant in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. Blood 1987; 70: 116-121.
Walters MC, Sullivan KM, Bernaudin F et al. Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. Blood 1995; 85: 879-884.
Abboud MR, Jackson SM, Barredo J et al. Neurologic complications following bone marrow transplantation for sickle cell disease. Bone Marrow Transplant 1996; 17: 405-407.
Ferster A, Corazza F, Vertongen F et al. Transplanted sickle-cell disease patients with autologous bone marrow recovery after graft failure develop increased levels of fetal haemoglobin which corrects disease severity. Br J Haematol 1995; 90: 804-808.
Brichard B, Vermylen C, Ninane J, Cornu G. Persistence of fetal hemoglobin production after successful transplantation of cord blood stem cells in a patient with sickle cell anemia. J Pediatr 1996; 128: 241-243.
Eisner MD, August CS. Impact of donor and recipient characteristics on the development of acute and chronic graft-versushost disease following pediatric bone marrow transplantation. Bone Marrow Transplant 1995; 15: 663-668.
Bernaudin F, Souillet G, Vannier JP et al. Report of the French experience concerning 26 children transplanted for severe sickle cell disease. Bone Marrow Transplant 1997; 19 (Suppl. 2): 112-115.
Giardini C, Galimberti M, Lucarelli G et al. Bone marrow transplantation in sickle cell disorders in Pesaro. Bone Marrow Transplant 1997; 19 (Suppl. 2): 106-109.
Sullivan KM, Walters MC, Patience M et al. Collaborative study of marrow transplantation for sickle cell disease: aspects specific for transplantation of hemoglobin disorders. Bone Marrow Transplant 1997; 19 (Suppl. 2): 102-105.
De Sanctis V, Galimberti M, Lucarelli G et al. Gonadal function after allogenic bone marrow transplantation for thalassemia. Arch Dis Child 1991; 66: 517-520.
Borgna-Pignatti C, Marradi P, Rugolotto S, Marcolongo A. Successful pregnancy after bone marrow transplantation for thalassemia. Bone Marrow Transplant 1996; 18: 235-236.
Davies S. Bone marrow transplant for sickle cell disease: the dilemma. Blood Rev 1993; 7: 4-9.
Platt OS, Guinan EC. Bone marrow transplantation in sickle cell anemia - the dilemma of choice. New Engl J Med 1996; 335: 426-428.
Adams R, Mckie V, Nichols F et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. New Engl J Med 1992; 326: 605-610.
Friedman DF, Lukas MB, Jawad A et al. Alloimmunization to platelets in heavily transfused patients with sickle cell disease. Blood 1996; 88: 3216-3222.
Lucarelli G, Giardini C, Baronciani D. Bone marrow transplantation in thalassemia. Semin Hematol 1995; 32: 297-303.
Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versushost disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
